Esperion Therapeutics, Inc. (ESPR) reported Q4 2025 earnings of $0.22 per share, undershooting analysts’ estimates. The company generated $168.4M in revenue for the quarter.
Esperion Therapeutics develops and commercializes non-statin medicines for patients with elevated LDL cholesterol, including its marketed products NEXLETOL and NEXLIZET. The pharmaceutical company focuses on treating adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C.
A detailed analysis of Esperion Therapeutics, Inc’s quarter follows shortly on AlphaStreet.
This article was generated using AlphaStreet’s proprietary financial analysis technology and reviewed by our editorial team.
The post Esperion Therapeutics, Inc (ESPR) Misses Q4 EPS Estimates first appeared on Alphastreet.
